Diagnostic performance of magnetic resonance imaging and targeted biopsy results in men with indwelling urinary catheters A propensity score-matched study

磁共振成像和靶向活检对留置导尿管男性患者的诊断性能:一项倾向评分匹配研究

阅读:1

Abstract

INTRODUCTION: We sought to evaluate multiparametric magnetic resonance imaging (mpMRI) findings and biopsy results in men with an indwelling catheter undergoing prostate cancer screening. mpMRI is central to the evaluation of prostate cancer. Little is known about the effect of an indwelling urinary catheter on prostate mpMRI findings and the results of subsequent biopsies. METHODS: We retrospectively reviewed 5820 mpMRI exams performed from 2017-2023. Forty-eight patients underwent mpMRI with an indwelling urinary catheter. Using propensity score matching, patients were matched 1:1 for age, pre-biopsy prostate-specific antigen (PSA), and prostate volume. Clinical characteristics, mpMRI findings, and targeted biopsy results were compared between the groups. RESULTS: After propensity score matching, clinical characteristics of the study groups did not differ significantly. Prostate Imaging-Reporting & Data System (PI-RADS) distribution did not show a significant difference (p=0.51); PI-RADS ≥3 lesions were identified in 20/48 (42%) patients with indwelling catheters and in 18/50 (36%) patients without catheters. Among patients with a PI-RADS score ≥3, clinically significant prostate cancer (csPCa) was identified in 5/20 patients carrying catheters and 6/18 patients without catheters (p=0.152). A higher rate of any cancer was identified in patients without a catheter (67% vs. 35%, p=0.049). PSA >9.79 ng/ml predicted the finding of csPCa in patients carrying urinary catheters with PI-RADS ≥3 lesions. CONCLUSIONS: Our findings suggest no significant difference in mpMRI findings and csPCa rates for patients with and without indwelling urinary catheters. Patients carrying urinary catheters suspected to harbor csPCa based on an elevated PSA level should undergo further evaluation, including mpMRI and biopsies when necessary before benign prostatic hyperplasia treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。